Skip to content
The Policy VaultThe Policy Vault

Epidiolex (cannabidiol oral solution)Highmark

Dravet syndrome (DS)

Preferred products

  • valproic acid
  • divalproex sodium
  • topiramate
  • clobazam

Initial criteria

  • age ≥ 1 year
  • diagnosis of Dravet syndrome (ICD-10: G40.83)
  • treatment is in combination with other conventional agents
  • therapeutic failure, contraindication, or intolerance to at least two of the following generic products: valproic acid or divalproex sodium, plan-preferred topiramate, clobazam

Reauthorization criteria

  • prescriber attests that the member has experienced a reduction in seizure frequency from baseline

Approval duration

12 months